Omeprazole (73590-58-6) is a H⁺,K⁺-ATPase inhibitor (IC₅₀ = 5.8 μM). Clinically useful antisecretory and antiulcer agent.¹ Potent inhibitor of CYP2C19 (K_i=3.1 mM).² Inhibits swelling-dependent chloride channels.³ Facilitates oral bioavailability of bioactive peptides such as oxytocin by raising stomach pH.⁴ Displays broad spectrum antiviral activity.⁵ Enhances efficacy of remdesivir (10-fold).⁶

References/Citations:

1) Satoh et al. (1989), Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats; J. Pharmacol. Exp. Ther., 248 806
2) Kuzin et al. (2018), Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine; Clin. Pharmacokinet, 57 729
3) Schmarda et al. (2000) The gastric H,K-ATPase blocker Iansoprazole is an inhibitor of chloride channels; Br. J. Pharmacol., 129 598
4) Maejima et al. (2020), Oral oxytocin delivery with proton pump inhibitor pretreatment decreases food intake; Peptides, 128 170312
5) Wantanabe et al. (2020), Selective Targeting of Virus Replication by Proton Pump Inhibitors; Sci. Rep., 10 4003
6) Bojkova et al. (2020), SARS-CoV2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles; bioRxiv, epub ahead of print DOI: 10.1101/2020.04.03.024257